ArticleMedicine2026
Prognostic value of the international normalized ratio-to-albumin ratio in coronary artery disease: A retrospective cohort study from the MIMIC-IV database.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD) is a major cause of mortality in the intensive care units. The prothrombin time-international normalized ratio-to-albumin ratio (PTAR), integrating coagulation status and nutritional/inflammatory conditions, may provide additional prognostic information. This study aimed to evaluate the prognostic value of PTAR in predicting the mortality risk in critically ill patients with CAD. We conducted a retrospective cohort study using the Medical Information Mart for Intensive Care IV database to evaluate the relationship between PTAR and all-cause mortality. Adult CAD was categorized into quartiles according to PTAR levels. Cox proportional-hazards models were constructed to explore the independent association between PTAR and 28-day mortality, with progressive adjustment for potential confounders. Restricted cubic spline analysis, Kaplan-Meier survival curves, and receiver operating characteristic analysis were performed to assess dose-response patterns, survival differences, and predictive performance. Subgroup and interaction analyses were also conducted across the major clinical strata. Elevated PTAR levels were independently associated with increased mortality. The 28-day and 365-day all-cause mortality rates were 18.7% and 22.6%, respectively. Receiver operating characteristic analysis demonstrated a moderate discriminatory ability for PTAR (area under the curve = 0.667), which was significantly improved when combined with the Sequential Organ Failure Assessment score (area under the curve = 0.727, P < .001). Restricted cubic spline analysis revealed a nonlinear dose-response relationship between PTAR and mortality (P < .001). Subgroup analyses showed consistent results across most clinical strata, except for race. Elevated PTAR is independently and significantly associated with increased all-cause mortality in critically ill CAD patients. Its combination with the Sequential Organ Failure Assessment score improves the prognostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.